

**REMARKS**

Applicants elect to prosecute the invention of Group XXV presented in claims 1-5, 9, 11-15 and 25 which are drawn to a method of preventing or treating male erectile dysfunction or female sexual arousal disorder by administering bFGF protein. Claims 2-3, 6-8, 10, 16-20 and 22 have been canceled as directed to non-elected inventions. The remaining claims, claims 1-5, 9, 11-15 and 21, have been amended to conform to this election. New claims 23, 25 and 27 are supported, for example, in paragraph 74 of the specification on page 20, which indicates that various combinations of VEGF and BDNF can be administered with bFGF. Support for new claims 24, 26 and 28 is found in claim 21 as originally filed, which depends from claim 1 listing all three proteins. No new matter has been added and entry of the amendment is respectfully requested.

Examination on the merits is now requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 220022001610.

Respectfully submitted,

Dated: October 3, 2006

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive  
Suite 100  
San Diego, California 92130-2040  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125